Skip to content

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02710331
Acronym
THC-ETOH-III
Enrollment
40
Registered
2016-03-16
Start date
2016-03-31
Completion date
2025-12-31
Last updated
2025-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs

Brief summary

The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.

Detailed description

To study the effects of ethanol clamped at BAC 0.04% (equivalent to consuming approximately 2 drinks over 1 hour) and oral Dronabinol (10 mg capsule) on driving.

Interventions

10 mg capsule of Dronabinol will be administered orally.

DRUGPlacebo

Control: no alcohol, administered for \ 80 minutes.

Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Males or females 21 to 55 years of age (extremes included). * Exposed to cannabis at least once. * Exposed to alcohol at least once. * Able to provide informed consent.

Exclusion criteria

* Cannabis naïve * Alcohol naïve * Positive pregnancy screen * Hearing deficits * Sesame oil allergy

Design outcomes

Primary

MeasureTime frame
Change from Baseline: Road Tracking Errorbaseline, +100, +210 mins after start of dronabinol administration

Secondary

MeasureTime frameDescription
Change from Baseline: Visual Analog Scale (VAS)baseline, +60, +90, +210, +360 mins after start of dronabinol administrationFeeling states associated with alcohol and cannabis intoxication will be measured using this self-report scale of feeling states.
Change from Baseline: Cognitive Test Batterybaseline, +120 mins after start of dronabinol administrationSeveral computer tasks will be administered to assess alcohol and THC effects on driving related cognition, including: visual vigilance, visual motor function, attention and working memory, and processing speed.
Change from Baseline: Biphasic Alcohol Effects Scale (BAES)baseline, +60, +90, +210, +360 mins after start of dronabinol administrationA scale designed to assess the stimulant and sedative effects associated with alcohol intoxication.
Change from Baseline: Number of Joints Scalebaseline, +60, +90, +210, +360 mins after start of dronabinol administrationSubjects will be asked to rate the number of standard joints that they believe they have been administered.
Change from Baseline: Number of Drinks Scalebaseline, +60, +90, +210, +360 mins after start of dronabinol administrationSubjects will be asked to rate the number of standard drinks that they believe they have been administered.
Change from Baseline: Willingness to Drive Scalebaseline, +60, +90, +210, +360 mins after start of dronabinol administrationSubjects will be asked to rate their willingness to drive at their current state in the context of various scenarios including willingness to drive from testing facility to a number of destinations that are different driving distances.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026